Odyssey Group International (ODYY) 10-Q 21 Jun 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Apr. 30, 2021	Jun. 21, 2021
Cover [Abstract]
Entity Registrant Name	Odyssey Group International, Inc.
Entity Central Index Key	0001626644
Document Type	10-Q
Document Period End Date	Apr. 30, 2021
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		96,891,168
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Entity Small Business	true
Entity Emerging Growth	false
Entity Shell Company	false
Entity Interactive data current	Yes
Entity File Number	000-56196
Entity Incorporation State Country Code	NV

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - USD ($)	Apr. 30, 2021	Jul. 31, 2020
Current Assets:
Cash	$ 1,378,225	$ 62,952
Prepaid expenses	75,000	36,667
Total current assets	1,453,225	99,619
Property and equipment, net of accumulated depreciation of $2,758 and $2,345	552	965
Intangible assets, net of accumulated amortization of $50,000 and $45,000	0	5,000
Total Assets	1,453,777	105,584
Current liabilities:
Accounts payable	338,845	269,388
Accrued wages	246,872	211,702
Accrued interest	14,098	14,742
Asset purchase liability	1,125,026	0
Notes payable, net of unamortized beneficial conversion feature, debt discount and closing costs of $616,183 and $233,770	675,847	211,231
Total current liabilities	2,400,688	707,063
Long-term debt	0	50,000
Total liabilities	2,400,688	757,063
Shareholders' deficit:
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.001 par value, 500,000,000 shares authorized, 101,539,105 and 88,559,978 shares issued and outstanding	101,539	88,560
Additional paid-in capital	41,784,782	28,110,689
Accumulated deficit	(42,833,232)	(28,850,728)
Total stockholders' deficit	(946,911)	(651,479)
Total liabilities and stockholders' deficit	$ 1,453,777	$ 105,584

Balance Sheets (Unaudited) (Par

Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Apr. 30, 2021	Jul. 31, 2020
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 2,758	$ 2,345
Accumulated amortization	50,000	45,000
Unamortized debt discount	$ 616,183	$ 233,770
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	101,539,105	88,559,978
Common Stock, Shares Outstanding	101,539,105	88,559,978

Statements of Operations and Co

Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Income Statement [Abstract]
General and administrative expense	$ 2,654,320	$ 867,665	$ 3,813,380	$ 2,690,140
In-process research and development	9,440,000	0	9,440,000	0
Loss from operations	(12,094,320)	(867,665)	(13,253,380)	(2,690,140)
Interest expense	357,370	131,610	779,124	326,692
Other income	(50,000)	0	(50,000)	0
Net loss and comprehensive loss	$ (12,401,690)	$ (999,275)	$ (13,982,504)	$ (3,016,832)
Basic and diluted net loss per share	$ (0.13)	$ (0.01)	$ (0.15)	$ (0.02)
Shares used for basic and diluted net loss per share	98,382,540	87,170,622	93,135,527	87,113,296

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, shares at Jul. 31, 2019	86,990,400
Beginning balance, value at Jul. 31, 2019	$ 86,990	$ 23,821,124	$ (24,501,872)	$ (593,758)
Stock-based compensation		1,048,312		1,048,312
Warrants and beneficial conversion feature issued with convertible notes		85,430		85,430
Net loss			(1,416,612)	(1,416,612)
Ending balance, shares at Oct. 31, 2019	86,990,400
Ending balance, value at Oct. 31, 2019	$ 86,990	24,954,866	(25,918,484)	(876,628)
Common stock issued for services, shares	200,000
Common stock issued for services, value	$ 200	269,800		270,000
Stock-based compensation		181,874		181,874
Net loss			(600,945)	(600,945)
Ending balance, shares at Jan. 31, 2020	87,190,400
Ending balance, value at Jan. 31, 2020	$ 87,190	25,406,540	(26,519,429)	(1,025,699)
Common stock issued for services, shares
Common stock issued for services, value		546,708		546,708
Warrants and beneficial conversion feature issued with convertible notes		250,000		250,000
Net loss			(999,275)	(999,275)
Ending balance, shares at Apr. 30, 2020	87,190,400
Ending balance, value at Apr. 30, 2020	$ 87,190	26,203,248	(27,518,704)	(1,228,266)
Beginning balance, shares at Jul. 31, 2020	88,559,978
Beginning balance, value at Jul. 31, 2020	$ 88,560	28,110,689	(28,850,728)	(651,479)
Conversion of convertible note payable, shares	214,000
Conversion of convertible note payable, value	$ 214	106,786		107,000
Stock-based compensation		130,301		130,301
Common stock issued in debt financing, shares	420,000
Common stock issued in debt financing, value	$ 420	196,980		197,400
Common stock issued in equity financing, shares	1,396,224
Common stock issued in equity financing, value	$ 1,396	248,604		250,000
Stock forfeited, shares	(20,000)
Stock forfeited, value	$ (20)			(20)
Warrants issued in connection with debt and equity financings		128,333		128,333
Net loss			(711,514)	(711,514)
Ending balance, shares at Oct. 31, 2020	90,570,202
Ending balance, value at Oct. 31, 2020	$ 90,570	28,921,693	(29,562,242)	(549,979)
Common stock issued for services, shares	540,000
Common stock issued for services, value	$ 540	69,460		70,000
Stock-based compensation		111,728		111,728
Common stock issued to LGH in connection with debt financing, shares	300,000
Common stock issued to LGH in connection with debt financing, value	$ 300	83,700		84,000
Common stock issued to LPC in connection with equity financing, shares	200,000
Common stock issued to LPC in connection with equity financing, value	$ 200	34,880		35,080
Beneficial conversion feature of LGH financing		19,780		19,780
Warrants issued in connection with debt and equity financings		82,720		82,720
Net loss			(869,300)	(869,300)
Ending balance, shares at Jan. 31, 2021	91,610,202
Ending balance, value at Jan. 31, 2021	$ 91,610	29,323,961	(30,431,542)	(1,015,971)
Common stock issued for services, shares	100,000
Common stock issued for services, value	$ 100	123,150		123,250
Stock-based compensation		887,437		887,437
Common stock issued in asset purchase agreement, shares	6,000,000
Common stock issued in asset purchase agreement, value	$ 6,000	8,254,000		8,260,000
Common stock issued in debt financing, shares	298,165
Common stock issued in debt financing, value	$ 298	245,802		246,100
Conversion of convertible note debt financing in connection with LGH, shares	594,000
Conversion of convertible note debt financing in connection with LGH, value	$ 594	88,506		89,100
Common stock issued in equity financing, shares	1,485,834
Common stock issued in equity financing, value	$ 1,486	1,213,014		1,214,500
Common stock issued in connection with LPC share purchase, shares	1,350,904
Common stock issued in connection with LPC share purchase, value	$ 1,351	1,185,044		1,186,395
Common stock issued in connection with LGH financing, shares	100,000
Common stock issued in connection with LGH financing, value	$ 100	40,865		40,965
Warrants issued in connection with debt financings		423,003		423,003
Net loss			(12,401,690)	(12,401,690)
Ending balance, shares at Apr. 30, 2021	101,539,105
Ending balance, value at Apr. 30, 2021	$ 101,539	$ 41,784,782	$ (42,833,232)	$ (946,911)

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Cash flows from operating activities:
Net loss	$ (13,982,504)	$ (3,016,832)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	5,413	7,915
Stock-based compensation	1,129,446	2,046,895
Stock issued for services	193,250	0
Debt Discount from beneficial conversion feature, warrants closing cost and inducement shares	(125,202)	0
Amortization of beneficial conversion feature, debt discount and closing costs	718,989	352,384
In-process R& D	8,260,000	0
Financing costs paid with stock	169,000	0
Gain on forgiveness of long-term debt	(50,000)	0
(Increase) decrease in prepaid expenses	(38,333)	158,932
Increase (decrease) in accounts payable	69,457	17,173
Increase in accrued wages	35,170	17,399
Increase in accrued interest	29,056	75,681
Decrease in asset purchase liability	1,125,026	0
Net cash used in operating activities	(2,461,232)	(340,453)
Cash flows from investing activities:	0	0
Cash flows from financing activities:
Proceeds from note payable	1,565,000	200,000
Financing closing costs paid with cash	(169,000)	0
Principal payments made on notes payable	(305,470)	0
Proceeds from equity financing	2,685,975	0
Net cash provided by financing activities	3,776,505	200,000
Increase (decrease) in cash	1,315,273	(140,453)
Cash, beginning of period	62,952	167,095
Cash, end of period	1,378,225	26,642
Supplemental disclosure of cash flow information
Cash paid for interest	30,310	0
Beneficial conversion feature related to notes payable	0	335,430
Note receivable related to a note payable	0	100,000
Common stock issued for conversion of notes payable and related accrued interest	442,200	0
Common stock issued for debt financing commitment shares	197,400	0
Warrants issued in connection with financings	634,056	0
Original issue discount on debt	169,200	0
Stock issued in exchange for closing costs	124,965	0
Beneficial conversion feature recognized	$ 19,780	$ 0

1. Basis of Presentation and Na

1. Basis of Presentation and Nature of Operations	9 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Nature of Operations	Note 1. Basis of Presentation and Nature of Operations Basis of Presentation The accompanying financial information of Odyssey Group International, Inc. is unaudited and has been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). However, such information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods. The financial information as of July 31, 2020 is derived from our 2020 Annual Report on Form 10-K. The financial statements included herein should be read in conjunction with the financial statements and the notes thereto included in our 2020 Annual Report on Form 10-K filed with the SEC on November 16, 2020. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year. Significant Accounting Policies Our significant accounting policies have not changed during the nine months ended April 30, 2021 from those disclosed in our Annual Report on Form 10-K for the year ended July 31, 2020. Research and Development Research and development expense is expensed as incurred as a component of General and administrative expense and totaled $565,764 and $608,383 for the three and nine months ended April 30, 2021, respectively, and $0 and $10,000 for the three and nine months ended April 30, 2020, respectively. In-process Research and Development In-process research and development is expensed upon purchase and totaled $9,440,000 for the three and nine months ended April 30, 2021, and $0 for the three and nine months ended April 30, 2020. See Note 3 to Notes to Financial Statements for additional information. Reclassifications Certain immaterial reclassifications were made to the prior period financial statements to conform to the current period presentation. There was no effect on our Statements of Operations and Comprehensive Loss or Statements of Cash Flows. Nature of Operations Our business model is to develop or acquire medical related products, engage third parties to help develop and manufacture such products and then distribute the products through various distribution channels, including third parties. We have acquired four different technologies; the CardioMap® heart monitoring and screening device, the Save a Life choking rescue device and two unique neurosteroid drug compounds intended to treat rare brain disorders and mild brain trauma (concussions). We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We plan to license, improve and develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly, as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third-party research and development firms who specialize in the creation of our products and we will apply for trademarks and patents as we develop proprietary products. We are not currently selling or marketing any products, as our products are in various stages of development and Food and Drug Administration ("FDA") clearance or approval to market our products will be required in order to sell in the United States.

2. New Accounting Pronouncement

2. New Accounting Pronouncements	9 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
New Accounting Pronouncements	Note 2. New Accounting Pronouncements ASU 2019-12 In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, “Income Taxes (Topic 740),” which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption of the amendments is permitted, including adoption in any interim period for which financial statements have not yet been issued. Depending on the amendment, adoption may be applied on the retrospective, modified retrospective or prospective basis. We do not expect the adoption of ASU 2019-12 to have a material effect on our financial position, results of operations or cash flows. ASU 2020-06 In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40),” which simplifies the accounting for convertible instruments, reduces complexity for preparers and practitioners and improves the decision usefulness and relevance of the information provided to financial statement users. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. We have not yet determined the impact of adoption this standard on our financial position, results of operations or cash flows.

3. Asset Purchase Agreement

3. Asset Purchase Agreement	9 Months Ended
	Apr. 30, 2021
Notes to Financial Statements
Asset Purchase Agreement	Note 3. Asset Purchase Agreement On January 7, 2021, we entered into an Asset Purchase Agreement (the “APA”) with Prevacus, Inc. (“Prevacus”), pursuant to which we purchased the assets and all of the rights, interests and intellectual property in a certain drug program (PRV-002) for treating mild brain trauma (concussion) and the delivery device (collectively, the “Asset”) in exchange for (i) 7,000,000 shares of our common stock plus (ii) the Milestone Consideration. Prevacus is a related party, as we are party to a Joint Venture and Intellectual Property Purchase Agreement, entered into in June 2019 and its President, Dr. Jacob Vanlandingham, is a member of our Board of Directors. The Milestone Consideration (“Milestone”) may be earned by Prevacus as follows: (i) 2,000,000 shares of our Common Stock when the United States Patents are revived in our name by the U.S. Patent and Trademark Office and any international patents that have lapsed also revived in our name by the respective country’s patent offices. The value of shares issued shall not exceed $6,000,000 based on the price of our common stock on the date the payment is due; (ii) 1,000,000 shares of our common stock upon successful first dosing in a Phase I Clinical Trial for the Asset; (iii) 2,000,000 shares of our common stock upon the grant and issuance to us of a Patent for the Asset from the U.S. Patent and Trademark Office, the value of which shall not exceed $10,000,000 based on the price of our common stock on the date the payment is due; (iv) 1,000,000 shares of our common stock upon our receipt of net proceeds of at least $1,000,000 in a Non-Dilutive Financing relating directly to the development of the Asset within one year after the Closing Date or, in the event of any Non-Dilutive Financing submitted prior to the one year anniversary of the Closing Date, the milestone will stay effective until the second year anniversary of the Closing Date; (v) 2,000,000 shares of our common stock if we sell the Asset to a Third Party resulting in net proceeds to us of at least $50,000,000 after a Phase IB Clinical Trial for which we are the sponsor is complete, but prior to completion of a Phase II Clinical Trial. The value of the 2,000,000 shares related to this milestone shall not exceed $25,000,000 based on the price of our common stock on the date the payment is due; (vi) 4,000,000 shares of our common stock upon the successful completion of a Phase II Clinical Trial for the Asset that leads to (I) our sale of the Asset to a Third Party resulting in net proceeds to us of at least $50,000,000; or (II) the administration of the first dose in a Phase III Clinical Trial for the Assetfor which we are, or one of our affiliates or licensees is the sponsor; and (vii) 2,000,000 shares of our common stock after the first dosing in a Phase II Clinical Trial and the successful completion of a Phase 1B human clinical trial. All Milestone payments shall only be paid once, upon the initial achievement of the particular Milestone event. Odyssey, at its sole and absolute discretion shall determine if any Milestone event has occurred. To extent the related milestones are not achieved, the above-mentioned Milestone payments will terminate and cease to exist, and we will no longer be liable thereunder, if said Milestone is not completed within four years after the Closing Date. On March 1, 2021 (the “Closing Date”), our APA with Prevacus closed and we issued 6,000,000 shares of our common stock valued at the fair market value of $1.18 per share for the stock granted on the date of acquisition for $7,080,000. In addition, 1,000,000 shares of our common stock valued at $1.18 per share for $1,180,000 was recorded as a component of Additional Paid in Capital for the probability of earning the Milestone Consideration of first dosing in a Phase I Clinical Trial. In addition, we withheld 1,000,000 shares of our common stock valued at $1.18 per share, for $1,180,000, in exchange for our payment of certain liabilities of Prevacus. We determined that in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 730 Research and Development (ASC 730-10-25-2(c)) and pursuant to ASC 730-10-25-2(c), intangibles purchased from others for use in particular research and development projects and that have no alternative future use in research and development or otherwise, represent costs of research and development as acquired, and therefore are expensed when incurred. On March 1, 2021, the date of acquisition, we expensed $9,440,000 as In-process research and development. At April 30, 2021, our Asset purchase liability account balance was $1,125,026. The net change in the Asset purchase liability account will be released as shares at $1.18 per share once all liabilities have been paid. At April 30, 2021 we have contingent consideration related to the Milestones in the APA entered into March 1, 2021. According to the agreement, we will issue common stock at the fair value at date of meeting the Milestone Consideration (i) and (iii – vii). The fair value of the contingent consideration was reviewed and it was determined that based on the current status of the project (Level 3), the value was zero for the current period ended April 30, 2021 since it is not yet probable that we will meet the future Milestone consideration.

4. Fair Value

4. Fair Value	9 Months Ended
	Apr. 30, 2021
Accounting Changes and Error Corrections [Abstract]
Fair Value	Note 4. Fair Value The fair value of financial assets and liabilities are determined utilizing a three-level framework as follows: Level 1 – Observable inputs, such as unadjusted quoted prices in active markets, for substantially identical assets and liabilities. Level 2 – Observable inputs other than quoted prices within Level 1 for similar assets and liabilities. These include quoted prices for similar assets and liabilities in active markets, quoted prices for identical assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. If the asset or liability has a specified or contractual term, the input must be observable for substantially the full term of the asset or liability. Level 3 – Unobservable inputs that are supported by little or no market activity, generally requiring a significant amount of judgment by management. The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Further, although we believe our valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. We did not have any transfers of assets or liabilities measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3 during the nine months ended April 30, 2021 or the year ended July 31, 2020. The carrying values of cash, prepaid expenses, accounts payable and accrued wages approximate their fair value due to their short maturities. No changes were made to our valuation techniques during the quarter ended April 30, 2021. Contingent Liabilities At April 30, 2021 and July 31, 2020, we had contingent consideration related to the acquisition of intellectual property, know-how and patents for an anti-choking, life-saving medical device in fiscal 2019. According to the agreement, we will make a one-time cash payment totaling $250,000 upon FDA clearance of the device. The fair value of the contingent consideration is reviewed quarterly and determined based on the current status of the project (Level 3). We determined the value was zero at both periods since it is not yet probable that we will file for FDA clearance. Fixed-Rate Debt We have fixed-rate debt that is reported on our Balance Sheets at carrying value less unamortized debt discount and closing costs. The fair value of our fixed rate debt was calculated using a discounted cash flow methodology with estimated current interest rates based on similar risk profile and duration (Level 2). The carrying value, excluding unamortized debt discount and debt issuance costs, and the fair value of our fixed-rate long-term debt was as follows: April 30, 2021 July 31, 2020 Carrying value $ 1,292,030 $ 445,000 Fair value $ 1,233,415 $ 445,000 Non-Financial Assets Non-financial assets, such as Property and equipment and Intangible assets, are measured at fair value on a non-recurring basis when events or circumstances indicate that an impairment may have occurred. If we determine these assets to be impaired, they are reported at fair value as calculated during the period. No non-financial assets were recorded at fair value during the nine months ended April 30, 2021 or the fiscal year ended July 31, 2020.

5. Debt

5. Debt	9 Months Ended
	Apr. 30, 2021
Debt Disclosure [Abstract]
Debt	Note 5. Debt LGH Investments, LLC December 2020 Promissory Note On December 11, 2020, we entered into a Securities Purchase Agreement (the “2020 LGH Agreement ”) with LGH Investments, LLC (“LGH”), pursuant to which we entered into a $165,000 face value convertible promissory note which bore interest at a one-time rate of 8.0% applied to the face value and was due September 11, 2021 (the “2020 Note”). We received $150,000 from the issuance of the 2020 Note and incurred a $15,000 original issue discount and $7,500 closing costs, which were being amortized over the life of the 2020 Note. The 2020 Note was convertible at a price of $0.15 per share, subject to adjustment as provided in the 2020 Note. The 2020 LGH Agreement included the issuance of a five-year share purchase warrant exercisable for 470,000 shares of our common stock at a price of $0.35 per share and 200,000 shares of our common stock. The value of the 470,000 warrants was $82,720 and the value of the 200,000 shares of common stock was $40,000 for a total value of $122,720, which were being amortized over the life of the 2020 Note as closing costs. Additionally, 100,000 shares valued at $44,000 were expensed as financing costs when incurred. The conversion feature met the criteria for characterization as a beneficial conversion feature and, accordingly, we allocated $19,780 of the proceeds to the beneficial conversion feature, which was also being amortized over the life of the 2020 Note. On March 5, 2021, LGH notified us of their intent to convert their $165,000 convertible promissory note plus $13,200 of interest. We negotiated with them to convert $89,100 of the total into 594,000 shares of our common stock and paid the remaining $89,100 in cash. April 2021 Promissory Note On April 5, 2021, we entered into a Securities Purchase Agreement with LGH (“2021 LGH Agreement”) The 2021 Note is convertible at a price of $1.00 per share. If an Event of Default occurs as defined in the 2021 Note, the Outstanding Balance shall immediately increase to one hundred twenty percent (120%) of the Outstanding Balance immediately prior to the occurrence of the Event of Default and the conversion price will be $1.00 per share. The 2021 LGH Agreement included the issuance of a five-year share purchase warrant exercisable for 1,134,000 shares of our common stock at a price of $0.95 per share and 100,000 shares of our common stock. The value of the 1,134,000 warrants was $877,716, of which $423,003 was allocated as debt discount and the value of the 100,000 shares of common stock was $85,000 of which $40,965 was allocated as the fair value of the common shares, for a total value of $463,968 which is being amortized over the life of the Note. Labrys Fund, LP On August 14, 2020, we entered into a Securities Purchase Agreement (the “Labrys SPA”) with Labrys Fund, LP (“Labrys”), pursuant to which Labrys purchased a $350,000 (the “Principal Amount”) Self-Amortization Promissory Note (the “Note”) for $315,000 in cash with an original issuance discount of approximately 10%. In consideration for entering into the Labrys SPA, we issued 420,000 shares (the “Commitment Shares”) of our common stock with a value of $197,400. 350,000 of the Commitment Shares (the “Second Commitment Shares”) will be returned to us if the Note is fully repaid and satisfied on or prior to August 14, 2021 (the “Maturity Date”). The Note bears interest at 12% per year. Upon the occurrence of any “Event of Default,” the Note is convertible into shares of our common stock at a price per share equal to the closing bid price of the common stock on the trading day immediately preceding the date of conversion (the “Conversion Price”); provided, however The Note requires that we reserve from our authorized and unissued common stock a number of shares equal to the greater of: (a) 1,140,000 shares or (b) the sum of (i) the number of shares of common stock issuable upon conversion of or otherwise pursuant to the Note and such additional shares of common stock, if any, as are issuable on account of interest on the Note pursuant to the Labrys SPA issuable upon the full conversion of the Note (assuming no payment of the principal amount or interest) as of any issue date multiplied by (ii) one and a half. We are subject to penalties for failure to timely deliver shares to Labrys following a conversion request. The Labrys SPA and the Note contain covenants and restrictions common with this type of debt transaction. Furthermore, we are subject to certain negative covenants under the Labrys SPA and the Note, which we believe are customary for transactions of this type. At April 30, 2021, we were in compliance with all covenants and restrictions. We paid Alliance Global Partners, LLP (“A.G.P.”) as a placement agent a fee of $25,200 and other closing costs of $6,500 for total closing costs of $31,700 which are being amortized over the one-year life of the Note. Conversion of Convertible Notes Payable On August 14, 2020, we converted a convertible promissory note with a face value of $100,000 and accrued interest of $7,000 into 214,000 shares of our common stock as calculated by the conversion price of the convertible promissory note of $0.50 per share. In February, March and April 2021, upon maturity, we converted five convertible promissory notes with an aggregate face value of $230,000 and aggregate accrued interest of $16,100 into 298,165 shares of our common stock as calculated by the conversion price of the convertible promissory notes with a weighted average conversion rate of $0.83 per share. In February 2021, we settled a convertible promissory note with a face value of $20,000 and accrued interest of $1,400 with a cash payment totaling $21,400. PPP Loan On February 11, 2021, we received notice that the SBA Paycheck Protection Program loan for $50,000 was forgiven. The $50,000 gain is reflected as Other income on our Statements of Operations for the three and nine months ended April 30, 2021. Notes Payable The following notes payable were outstanding: April 30, 2021 July 31, 2020 Convertible notes with maturities in May 2021 with interest rates of 7% and convertible at $0.80 per share $ 95,000 $ 445,000 Note issued to Labrys due August 14, 2021 with an interest rate of 12.0% 147,030 – Convertible note issued to LGH due February 5, 2022 with an interest rate of 8.0% and convertible at $1.00 per share 1,050,000 – 1,292,030 445,000 Unamortized debt discount and closing costs (616,183 ) 233,770 $ 675,847 $ 211,230

6. Share-based Payments

6. Share-based Payments	9 Months Ended
	Apr. 30, 2021
Share-based Payment Arrangement, Noncash Expense [Abstract]
Share-based Payments	Note 6. Share-based Payments Stock Options Stock option activity during the nine months ended April 30, 2021 was as follows: Number of Options Weighted Average Exercise Price Options outstanding at July 31, 2020 15,050,000 $ 0.26 Options canceled (15,000,000 ) 0.25 Options granted 1,000,000 1.18 Options outstanding at April 30, 2021 1,050,000 $ 1.22 On March 1, 2021, as part of the APA and Dr. Vanlandingham’s employment agreement, Dr. Vanlandingham was granted 1,000,000 stock options with a fair market value of $941,000. 250,000 shares vest on signing of closing documents. 250,000 shares vest on Phase 1A first dosing of human, 250,000 shares vest on Phase 1B first dosing of human; and 250,000 shares vest upon Company being accepted on NASDAQ. The foregoing table only includes stock options awarded to employees and others for services rendered to the Company. 600,000 options with an exercise price of $1.25 and a remaining term of 8.15 years issued as consideration for our acquisition of certain intellectual property assets are not reflected in the table above. Restricted Stock Units (“RSUs”) RSU activity during the nine months ended April 30, 2021 was as follows: RSUs outstanding at July 31, 2020 1,750,000 RSUs issued 4,775,000 RSUs vested (2,113,598 ) RSUs outstanding at April 30, 2021 4,411,402 In January 2021, we issued RSUs covering 4,000,000 shares of our common stock, with a value of $720,000, to two officers which vest equally over 36 months. In addition, we issued RSUs covering 50,000 shares of our common stock, with a value of $21,500, to a consultant, which vest equally over 24 months. In April 2021, we issued RSUs covering 50,000 shares of common stock to a consultant, with a value of $43,000 which vests in August 2021. These amounts are being expensed over the life of the awards and of these amounts, $88,465 was expensed to General and administrative expenses at April 30, 2021. In March and April 2021, we entered into consulting agreements with two medical professionals for our Science Advisory Board and eight individuals for our Sports Advisory Board. In connection with the agreements, we issued RSUs covering 675,000 shares of our common stock which vest 50% upon signing and 50% in one year. These amounts are being expensed over the life of the awards and of these amounts, $241,908 was expensed to General and administrative expenses at April 30, 2021. Unrecognized Compensation Costs At April 30, 2021, we had unrecognized stock-based compensation of $1,711,522, which will be recognized over the weighted average remaining vesting period of 1.4 years. In January 2021, the Compensation Committee agreed to provide Mr. Redmond 5,300,000 shares to replace the common stock shares agreed to in his December 2017 employment agreement that were never issued. The terms and conditions have not been determined but an agreement is under discussion. Warrants Warrant activity during the nine months ended April 30, 2021 was as follows: Number of Warrants Weighted Average Exercise Price Warrants outstanding at July 31, 2020 44,500 $ 1.50 Warrants issued 3,639,834 0.89 Warrants canceled (36,000 ) 1.50 Warrants outstanding at April 30, 2021 3,648,334 $ 0.89

7. Net Loss Per Share

7. Net Loss Per Share	9 Months Ended
	Apr. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	Note 7. Net Loss Per Share Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Potentially dilutive common stock and common stock equivalents, including stock options, RSUs and warrants are excluded as they would be antidilutive. The following anti-dilutive securities were excluded from the calculations of diluted net loss per share: Nine Months Ended April 30, 2021 2020 Options to purchase common stock 900,000 400,000 Shares issuable upon conversion of convertible notes and related accrued interest 1,183,691 1,355,278 Warrants to purchase common stock 3,648,334 50,000 Restricted stock units 2,113,598 750,000 Total potentially dilutive securities 7,845,623 2,555,278

8. Common Stock Issuances

8. Common Stock Issuances	9 Months Ended
	Apr. 30, 2021
Equity [Abstract]
Common Stock Issuances	Note 8. Common Stock Issuances Conversion of Convertible Notes Payable On August 14, 2020, we converted a convertible promissory note with a face value of $100,000 and accrued interest of $7,000 into 214,000 shares of our common stock as calculated by the conversion price of the convertible promissory note of $0.50 per share. In February, March and April 2021, upon maturity, we converted five convertible promissory notes with an aggregate face value of $230,000 and aggregate accrued interest of $16,100 into 298,165 shares of our common stock as calculated by the conversion price of the convertible promissory notes of $0.83 per share. Private Placements In February 2021, we sold a total of 960,834 shares of our common stock to 11 accredited investors for total proceeds of $689,500. Warrants for 960,834 shares our common stock were issued to the investors with an average exercise price of $1.23. The warrants expire six months from the date of closing and have a fair value of $426,273 and are a component of the total proceeds value. In March 2021, we sold 525,000 Units at $1.00 per unit to 17 accredited investors for total proceeds of $525,000. Each Unit consisted of one share of our common stock and a right to purchase one share of our common stock $2.00. These rights expire one year from the date of closing and have a fair value of $250,950 and are a component of the total proceeds value. Common Stock issued for Services In January 2021, we entered into three agreements for consulting services to be provided. We granted the consultants 540,000 shares of our common stock with a value of $88,000 which was expensed as a component of General and administrative expenses. On February 12, 2021, we entered into an agreement for consulting services to be provided through February 2022. We granted the consultant 75,000 shares of our common stock with a value of $93,750 which was expensed as a component of General and administrative expenses. On March 1, 2021, we entered into an agreement for consulting services to be provided through February 2022. We granted the consultant 25,000 shares of our common stock with a value of $29,500 which was expensed as a component of General and administrative expenses. Lincoln Park Capital Fund On August 14, 2020, we entered into a Purchase Agreement (the “LPC Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park” or “LPC”). Pursuant to the LPC Purchase Agreement, we have the right, in our sole discretion, to sell to LPC up to $10,250,000 in shares of our common stock, from time to time over a 36-month period. In consideration for entering into the LPC Purchase Agreement, we issued 793,802 shares of our common stock to LPC. Upon entering into the LPC Purchase Agreement, we sold 602,422 shares of our common stock to LPC in an initial purchase for a total purchase price of $250,000. Thereafter, and subject to the conditions of the LPC Purchase Agreement and RRA, on any business day and subject to certain customary conditions, we may direct LPC to purchase to up to 200,000 shares of our common stock (such purchases, “Regular Purchases”). The amount of a Regular Purchase may increase up to 100,000 shares of common stock under certain circumstances based on the market price of the common stock. There are no limits on the price per share that LPC may pay to purchase common stock under the LPC Purchase Agreement, provided that LPC’s committed obligation under any Regular Purchase shall not exceed $50,000 unless the median aggregate dollar value of the volume of shares of common stock during the 20 consecutive trading day period ending on the date of the applicable Regular Purchase equals or exceeds $100,000, in which case LPC’s committed obligation under such single Regular Purchase shall not exceed $500,000. In addition, if we have directed LPC to purchase the full amount of common stock available as a Regular Purchase on a given day, we may direct LPC to purchase additional amounts as “accelerated purchases” and “additional accelerated purchases” as set forth in the LPC Purchase Agreement. The purchase price of shares of our common stock will be based on the then prevailing market prices of such shares at the time of sale. The LPC Purchase Agreement limits our sale of shares of common stock to LPC, and LPC’s purchase or acquisition of common stock from us, to an amount of common stock that, when aggregated with all other shares of our common stock then beneficially owned by LPC would result in LPC having beneficial ownership, at any single point in time, of more than 4.99% of the then total outstanding shares of our common stock. The LPC Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification and termination provisions. LPC has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our common stock. The LPC Purchase Agreement does not limit our ability to raise capital from other sources in our sole discretion; provided, however, that we shall not enter into any “Variable Rate Transaction” as defined in the LPC Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities, but excluding any “At-the-Market” offering with a registered broker-dealer, until the later of (i) the 36-month anniversary of the date of the LPC Purchase Agreement, and (ii) the 36-month anniversary of the Commencement Date (if the Commencement has occurred), in either case irrespective of any earlier termination of the LPC Purchase Agreement. The LPC Purchase Agreement may be terminated by us at any time and at our discretion without any cost to us. In connection with the LPC transaction, we engaged A.G.P. as a placement agent to help raise capital. A.G.P. introduced us to LPC, for which we agreed to pay A.G.P. a fee of 8% of the amount of the funds received from LPC, which totaled $20,000 in the quarter ended October 31, 2020. A.G.P. will also receive a fee totaling 8% of any additional funds raised pursuant to the LPC Purchase Agreement. In addition, and in consideration for the service provided in connection with Labrys and LPC, we granted warrants that were immediately exercisable for a total of 550,000 shares of our common stock at $0.50 per share to A.G.P. and two partners of A.G.P. The warrants had a value of $220,000 and expire August 6, 2024. Of the $220,000, $91,667 was netted against the LPC equity transaction and $128,333 was recorded as debt closing costs related to the Labrys transaction and is being amortized over the one-year life of the note. Shares purchased by LPC, including the initial purchase, are summarized below: Purchase Date Number of Shares Purchased Average Purchase Price per Share Total Purchase Price Remaining Purchase Availability August 14, 2020 602,422 $ 0.410 $ 250,000 $ 10,000,000 January 2021 200,000 0.175 35,080 9,964,920 February 2021 330,106 0.626 206,798 9,758,122 March 2021 1,020,798 0.960 979,597 8,778,525 2,153,326 $ 1,221,475 We paid A.G.P. a fee of $97,718 in connection with the 1,550,904 shares purchased in 2021. The following table sets forth the remaining amount of gross proceeds we would receive from additional sales of our stock under the LPC Purchase Agreement at varying purchase prices as of April 30, 2021: Assumed Average Number of (1) Percentage of (2) Proceeds from (1) $0.10 17,118,038 17% $ 3,183,279 0.25 17,118,038 17% 5,750,984 0.81 (3) 10,837,685 12% 10,250,000 1.00 8,778,525 10% 10,250,000 1.25 7,022,820 9% 10,250,000 1.50 5,852,350 8% 10,250,000 (1) Although the Purchase Agreement provides that we may sell up to an additional $8,778,525 of our common stock to LPC, depending on the assumed average price per share, we may or may not be able to ultimately sell to Lincoln Park a number of shares of our common stock with a total value of $10,000,000 as the maximum number of shares to be sold totals 20,065,166. Following purchases and issuances made to date, 17,118,038 shares remained as of April 30, 2021. (2) The numerator is based on the maximum number of shares purchased at the corresponding assumed purchase price plus the 2,153,326 shares owned by LPC at April 30, 2021. The denominator is based on 96,391,168 shares outstanding as of April 30, 2021 plus the number of shares assumed purchased. The table does not give effect to the prohibition contained in the LPC Purchase Agreement that prevents us from selling to LPC the number of shares such that, after giving effect to such sale, LPC and its affiliates would beneficially own more than 4.99% of the then outstanding shares of our common stock. (3) The closing price of our common stock on April 30, 2021.

9. Related Party Transactions

9. Related Party Transactions	9 Months Ended
	Apr. 30, 2021
Income Tax Disclosure [Abstract]
Related Party Transactions	Note 9. Related Party Transactions Due to Officers and Executives The following amounts were due to our officers and were included in Accounts payable on our Balance Sheets: April 30, 2021 July 31, 2020 Joseph M. Redmond, CEO $ 574 $ 2,304 Christine Farrell, CFO 803 25,598 $ 1,377 $ 27,902 The $1,377 is for reimbursement of accrued expenses due the officers. The amount of salary due to Mr. Redmond for his services was included in Accrued wages on our Balance Sheets and was as follows: Balance at July 31, 2020 $ 183,846 Salary accrued – Salary paid – Balance at April 30, 2021 $ 183,846 Accrued wages on our balance sheet is $246,872 and includes accrued wages and payroll taxes payable, which includes $10,769 of increased officer wages for our CEO and CFO, per their employment agreements entered into on January 21, 2021. Related Party Transaction On March 1, 2021, as part of the APA and Dr. Vanlandingham’s employment agreement, Dr. Vanlandingham was granted 1,000,000 stock options with a fair market value of $941,000. 250,000 shares vest on signing of closing documents. 250,000 shares vest on Phase 1A first dosing of human, 250,000 shares vest on Phase 1B first dosing of human; and 250,000 shares vest upon Company being accepted on NASDAQ.

10. Going Concern

10. Going Concern	9 Months Ended
	Apr. 30, 2021
Risks and Uncertainties [Abstract]
Going Concern	Note 10. Going Concern We did not recognize any revenues for the year ended July 31, 2020 or the nine months ended April 30, 2021 and we had an accumulated deficit of $42,833,232 as of April 30, 2021. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations. Cash available at April 30, 2021 of $1,378,225 may not provide enough working capital to meet our current operating expenses through June 21, 2022. The operating deficit indicates substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to further scale down or perhaps even cease operations. The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty. Additionally, as the novel coronavirus (“COVID-19”) pandemic continues to severely impact the U.S. and global economy, our business may be impacted in a variety of ways. Political, legal or regulatory actions as a result of the COVID-19 pandemic in jurisdictions where we may plan to manufacture, source or distribute products have created supply disruptions which could affect our plans, and may cause additional supply disruptions or shortages in the future. We cannot currently predict the frequency, duration or scope of these governmental actions and supply disruptions. For example, several countries, including India and China, have increased or instituted new restrictions on the export of medical or pharmaceutical products that we distribute or use in our business, including key components or raw materials. Governmental authorities in many countries, including the U.S., are enacting legislative or regulatory changes to address the impact of the pandemic, which may restrict or require changes in our operations, increase our costs, or otherwise adversely affect our operations. If we are unable to raise additional capital by June 21, 2022, we will adjust our current business plan. Due to the unknown and volatile nature of the stock price and trading volume of our common stock, is it is difficult to predict the timing and amount of availability pursuant to our equity line of credit with LPC (see Note 8 above). Given our recurring losses, negative cash flow, accumulated deficit, and the impact of COVID-19, there is substantial doubt about our ability to continue as a going concern.

11. Subsequent Events

11. Subsequent Events	9 Months Ended
	Apr. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 11. Subsequent Events Conversion of Convertible Notes Payable In May 2021, upon maturity, we converted four convertible promissory notes with an aggregate face value of $95,000 and accrued interest of $6,650 into 127,063 shares of our common stock as calculated by the conversion price of the convertible promissory notes of $0.80 per share. Private Placement In June 2021, we sold 500,000 shares of our common stock at $0.59 per share along with a five-year share purchase warrant exercisable for 500,000 shares of our common stock at a price of $1.00 per share for total an aggregate purchase price of $295,000 to an accredited investor which also provided certain consulting services to the Company. The purchase price was paid with $250,000 cash and the satisfaction of $45,000 of amounts due to the investor for its consulting services. Treasury Shares In June, 2021, Green Energy Alternatives, Inc. returned 5,300,000 shares of stock to our common stock treasury, as the company is no longer in business.

1. Basis of Presentation and _2

1. Basis of Presentation and Nature of Operations (Policies)	9 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial information of Odyssey Group International, Inc. is unaudited and has been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). However, such information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods. The financial information as of July 31, 2020 is derived from our 2020 Annual Report on Form 10-K. The financial statements included herein should be read in conjunction with the financial statements and the notes thereto included in our 2020 Annual Report on Form 10-K filed with the SEC on November 16, 2020. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year.
Significant Accounting Policies	Significant Accounting Policies Our significant accounting policies have not changed during the nine months ended April 30, 2021 from those disclosed in our Annual Report on Form 10-K for the year ended July 31, 2020.
Research and Development Expense	Research and Development Research and development expense is expensed as incurred as a component of General and administrative expense and totaled $565,764 and $608,383 for the three and nine months ended April 30, 2021, respectively, and $0 and $10,000 for the three and nine months ended April 30, 2020, respectively.
In-process Research and Development	In-process Research and Development In-process research and development is expensed upon purchase and totaled $9,440,000 for the three and nine months ended April 30, 2021, and $0 for the three and nine months ended April 30, 2020. See Note 3 to Notes to Financial Statements for additional information.
Reclassifications	Reclassifications Certain immaterial reclassifications were made to the prior period financial statements to conform to the current period presentation. There was no effect on our Statements of Operations and Comprehensive Loss or Statements of Cash Flows.
Nature of Operations	Nature of Operations Our business model is to develop or acquire medical related products, engage third parties to help develop and manufacture such products and then distribute the products through various distribution channels, including third parties. We have acquired four different technologies; the CardioMap® heart monitoring and screening device, the Save a Life choking rescue device and two unique neurosteroid drug compounds intended to treat rare brain disorders and mild brain trauma (concussions). We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We plan to license, improve and develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly, as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third-party research and development firms who specialize in the creation of our products and we will apply for trademarks and patents as we develop proprietary products. We are not currently selling or marketing any products, as our products are in various stages of development and Food and Drug Administration ("FDA") clearance or approval to market our products will be required in order to sell in the United States.

4. Fair Value (Tables)

4. Fair Value (Tables)	9 Months Ended
	Apr. 30, 2021
Accounting Changes and Error Corrections [Abstract]
Schedule of Fixed-Rate Debt	The carrying value, excluding unamortized debt discount and debt issuance costs, and the fair value of our fixed-rate long-term debt was as follows: April 30, 2021 July 31, 2020 Carrying value $ 1,292,030 $ 445,000 Fair value $ 1,233,415 $ 445,000

5. Debt (Tables)

5. Debt (Tables)	9 Months Ended
	Apr. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Notes Payable	The following notes payable were outstanding: April 30, 2021 July 31, 2020 Convertible notes with maturities in May 2021 with interest rates of 7% and convertible at $0.80 per share $ 95,000 $ 445,000 Note issued to Labrys due August 14, 2021 with an interest rate of 12.0% 147,030 – Convertible note issued to LGH due February 5, 2022 with an interest rate of 8.0% and convertible at $1.00 per share 1,050,000 – 1,292,030 445,000 Unamortized debt discount and closing costs (616,183 ) 233,770 $ 675,847 $ 211,230

6. Share-based Payments (Tables

6. Share-based Payments (Tables)	9 Months Ended
	Apr. 30, 2021
Debt Disclosure [Abstract]
Schedule of stock option activity	Number of Options Weighted Average Exercise Price Options outstanding at July 31, 2020 15,050,000 $ 0.26 Options canceled (15,000,000 ) 0.25 Options granted 1,000,000 1.18 Options outstanding at April 30, 2021 1,050,000 $ 1.22
Schedule of RSU activity	RSUs outstanding at July 31, 2020 1,750,000 RSUs issued 4,775,000 RSUs vested (2,113,598 ) RSUs outstanding at April 30, 2021 4,411,402
Schedule of warrant activity	Number of Warrants Weighted Average Exercise Price Warrants outstanding at July 31, 2020 44,500 $ 1.50 Warrants issued 3,639,834 0.89 Warrants canceled (36,000 ) 1.50 Warrants outstanding at April 30, 2021 3,648,334 $ 0.89

7. Net Loss Per Share (Tables)

7. Net Loss Per Share (Tables)	9 Months Ended
	Apr. 30, 2021
Equity [Abstract]
Schedule of Net Loss Per Share	Nine Months Ended April 30, 2021 2020 Options to purchase common stock 900,000 400,000 Shares issuable upon conversion of convertible notes and related accrued interest 1,183,691 1,355,278 Warrants to purchase common stock 3,648,334 50,000 Restricted stock units 2,113,598 750,000 Total potentially dilutive securities 7,845,623 2,555,278

8. Common Stock Issuances (Tabl

8. Common Stock Issuances (Tables)	9 Months Ended
	Apr. 30, 2021
Equity [Abstract]
Schedule of Shares purchased	Shares purchased by LPC, including the initial purchase, are summarized below: Purchase Date Number of Shares Purchased Average Purchase Price per Share Total Purchase Price Remaining Purchase Availability August 14, 2020 602,422 $ 0.410 $ 250,000 $ 10,000,000 January 2021 200,000 0.175 35,080 9,964,920 February 2021 330,106 0.626 206,798 9,758,122 March 2021 1,020,798 0.960 979,597 8,778,525 2,153,326 $ 1,221,475
Schedule of Common Stock Issuances	Assumed Average Number of (1) Percentage of (2) Proceeds from (1) $0.10 17,118,038 17% $ 3,183,279 0.25 17,118,038 17% 5,750,984 0.81 (3) 10,837,685 12% 10,250,000 1.00 8,778,525 10% 10,250,000 1.25 7,022,820 9% 10,250,000 1.50 5,852,350 8% 10,250,000

9. Related Party Transactions (

9. Related Party Transactions (Tables)	9 Months Ended
	Apr. 30, 2021
Income Tax Disclosure [Abstract]
Schedule of Accounts payable	The following amounts were due to our officers and were included in Accounts payable on our Balance Sheets: April 30, 2021 July 31, 2020 Joseph M. Redmond, CEO $ 574 $ 2,304 Christine Farrell, CFO 803 25,598 $ 1,377 $ 27,902
Schedule of Accrued wages	The amount of salary due to Mr. Redmond for his services was included in Accrued wages on our Balance Sheets and was as follows: Balance at July 31, 2020 $ 183,846 Salary accrued – Salary paid – Balance at April 30, 2021 $ 183,846

1. Basis of Presentation and _3

1. Basis of Presentation and Nature of Operationsn (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Accounting Policies [Abstract]
Research and Development	$ 565,764	$ 0	$ 608,383	$ 10,000
In-process research and development	$ 9,440,000	$ 0	$ 9,440,000	$ 0

3. Asset Purchase Agreement (De

3. Asset Purchase Agreement (Details Narrative) - USD ($)	3 Months Ended		7 Months Ended	9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Mar. 01, 2021	Apr. 30, 2021	Apr. 30, 2020	Jul. 31, 2020
Research and development	$ 565,764	$ 0		$ 608,383	$ 10,000
Asset purchase liability	$ 1,125,026			$ 1,125,026		$ 0
Asset Purchase Agreement [Member] | Prevacus [Member]
Stock issued for assets, shares			7,000,000
Stock issued for assets, value			$ 7,080,000
Stock issued for probable Milestone consideration, shares			1,000,000
Stock issued for probable Milestone consideration, value			$ 1,180,000
Stock withheld for payment of liabilities, shares			1,000,000
Stock withheld for payment of liabilities, value			$ 1,180,000
Research and development			9,440,000
Asset purchase liability			$ 1,125,026

4. Fair Value (Details)

4. Fair Value (Details) - USD ($)	Apr. 30, 2021	Jul. 31, 2020
Fair Value Disclosures [Abstract]
Carrying value	$ 1,292,030	$ 445,000
Fair value	$ 1,233,415	$ 445,000

5. Debt (Details)

5. Debt (Details) - USD ($)	Apr. 30, 2021	Jul. 31, 2020
Notes Payable	$ 1,292,030	$ 445,000
Unamortized debt discount and closing costs	(616,183)	233,770
Notes Payable current	675,847	211,230
Convertible Notes
Notes Payable	95,000	445,000
Convertible Notes | LGH [Member]
Notes Payable	1,050,000	0
Notes [Member] | Labrys [Member]
Notes Payable	$ 147,030	$ 0

5. Debt (Details Narrative)

5. Debt (Details Narrative) - USD ($)	Aug. 14, 2020	Feb. 28, 2021	Apr. 30, 2021	Dec. 11, 2020	Feb. 28, 2021	Apr. 05, 2021	May 05, 2021	Apr. 30, 2021	Apr. 30, 2020
Proceeds from notes payable								$ 1,565,000	$ 200,000
Beneficial conversion feature								125,202	$ 0
Convertible Promissory Note [Member]
Debt converted, amount converted	$ 100,000
Debt converted, shares issued	214,000
Debt converted, interest converted	$ 7,000
Five Convertible Promissory Notes [Member]
Debt converted, amount converted								$ 230,000
Debt converted, shares issued								298,165
Debt converted, interest converted								$ 16,100
Convertible Promissory Note
Stock issued new, shares		100,000
Debt converted, amount converted	$ 100,000		$ 230,000
Debt converted, shares issued	214,000		298,165
Conversion price per share	$ 0.50	$ 0.83	$ 0.83		$ 0.83			$ 0.83
Repayment of convertible debt					$ 20,000
Interest paid					$ 1,400
PPP Loan [Member]
Gain on debt forgiveness								$ 50,000
2020 LGH Agreement [Member] | 2020 Note [Member] | LGH [Member]
Debt face amount				$ 165,000
Proceeds from notes payable				$ 150,000
Stock issued new, shares				200,000
Stock issued new, value				$ 40,000
Maturity date				Sep. 11, 2021
Debt interest rate				8.00%
Payment of stock issuance costs				$ 7,500
Debt converted, amount converted							$ 89,100
Debt converted, shares issued							594,000
Conversion price per share				$ 0.15
Proceeds from issuance of debt				$ 150,000
Original issue discount				15,000
Beneficial conversion feature				$ 19,780
Warrant issued				470,000
Warrant issued fair value				$ 82,720
Stock issued for financing costs, shares				100,000
custom:StockIssuedForFinancingCostsValue				$ 44,000
Repayment of convertible debt							$ 89,100
Total value of equity issued				$ 122,720
2021 LGH Agreement [Member] | April 2021 Promisssory Note [Member] | LGH [Member]
Debt face amount						$ 1,050,000
Proceeds from notes payable						$ 970,000
Stock issued new, shares						100,000
Stock issued new, value						$ 85,000
Maturity date						Feb. 5, 2022
Debt interest rate						8.00%
Payment of stock issuance costs						$ 30,000
Original issue discount						$ 50,000
Warrant issued						1,134,000
Warrant issued fair value						$ 877,716
Total value of equity issued						463,968
2021 LGH Agreement [Member] | April 2021 Promisssory Note [Member] | LGH [Member] | Debt Discount [Member]
Warrant issued fair value						423,003
2021 LGH Agreement [Member] | April 2021 Promisssory Note [Member] | LGH [Member] | Fair Value of Common Stock [Member]
Stock issued new, value						$ 40,965
Labrys SPA [Member] | Labrys Note [Member] | Labrys [Member]
Debt face amount	$ 350,000
Proceeds from notes payable	$ 315,000
Stock issued new, shares	420,000
Stock issued new, value	$ 197,400
Debt interest rate	12.00%
Payment of stock issuance costs	$ 25,200
Payment of other stock issuance costs	6,500
Total debt issuance costs	$ 31,700

6. Share-based Payments (Detail

6. Share-based Payments (Details - Option activity)	9 Months Ended
	Apr. 30, 2021$ / sharesshares
Number of Options
Options outstanding at beginning | shares	15,050,000
Options canceled | shares	(15,000,000)
Options granted	$ 1,000,000
Options outstanding at end | shares	1,050,000
Weighted Average Exercise Price
Options outstanding at beginning	$ 0.26
Options canceled	0.25
Options granted	1.18
Options outstanding at end	$ 1.22

6. Share-based Payments (Deta_2

6. Share-based Payments (Details - RSU Activity) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Apr. 30, 2021shares
RSUs outstanding, beginning balance	1,750,000
RSUs issued	4,775,000
RSUs vested	(2,113,598)
RSUs outstanding, ending balance	4,411,402

6. Share-based Payments (Deta_3

6. Share-based Payments (Details - Warrant Activity) - Warrants [Member]	9 Months Ended
	Apr. 30, 2021$ / sharesshares
Warrants outstanding, beginning balance | shares	44,500
Warrants issued | shares	3,639,834
Warrants canceled | shares	(36,000)
Warrants outstanding, ending balance | shares	3,648,334
Weighted average exercise price, beginning | $ / shares	$ 1.50
Weighted average exercise price, warrants issued | $ / shares	0.89
Weighted average exercise price, warrants canceled | $ / shares	1.50
Weighted average exercise price, ending | $ / shares	$ 0.89

6. Share-based Payments (Deta_4

6. Share-based Payments (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended	7 Months Ended	9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Jan. 31, 2021	Mar. 01, 2021	Apr. 30, 2021	Apr. 30, 2020
Unrecognized stock-based compensation	$ 1,711,522				$ 1,711,522
Weighted average remaining vesting period					1 year 4 months 24 days
General and administrative expenses	2,654,320	$ 867,665			$ 3,813,380	$ 2,690,140
Options granted					$ 1,000,000
Share-based compensation					$ 1,129,446	$ 2,046,895
Dr. Vanlandingham [Member]
Options granted				$ 1,000,000
Fair value of options granted				$ 941,000
Share-based compensation					490,104
Restricted Stock Units (RSUs) [Member]
General and administrative expenses					$ 88,465
Restricted Stock Units (RSUs) [Member] | Two officers [Member]
RSU's issued			4,000,000
RSU's issued, value			$ 720,000
Expiration period			24 months
Restricted Stock Units (RSUs) [Member] | Consultant [Member]
RSU's issued			50,000		50,000
RSU's issued, value	$ 43,000		$ 21,500		$ 43,000
Expiration period			24 months
Restricted Stock Units (RSUs) [Member] | Advisory Boards [Member]
RSU's issued					675,000
General and administrative expenses					$ 241,908

7. Net Loss Per Share (Details)

7. Net Loss Per Share (Details) - shares	9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Potentially dilutive securities	7,845,623	2,555,278
Options [Member]
Potentially dilutive securities	900,000	400,000
Convertible notes and related accrued interest [Member]
Potentially dilutive securities	1,183,691	1,355,278
Warrant [Member]
Potentially dilutive securities	3,648,334	50,000
Restricted Stock Units (RSUs) [Member]
Potentially dilutive securities	2,113,598	750,000

8. Common Stock Issuances (Deta

8. Common Stock Issuances (Details - LPC share purchases) - Lincoln Park Capital Fund - USD ($)	Aug. 14, 2020	Jan. 31, 2021	Feb. 28, 2021	Mar. 31, 2021	Apr. 30, 2021
Stock issued new, shares	602,422	200,000	330,106	1,020,798	2,153,326
Stock price per share	$ 0.410	$ 0.175	$ 0.626	$ .0960
Proceeds from sale of stock	$ 250,000	$ 35,080	$ 206,798	$ 979,597	$ 1,221,475
Remaining Purchase Availability	$ 10,000,000	$ 9,964,920	$ 9,758,122	$ 8,778,525

8. Common Stock Issuances (De_2

8. Common Stock Issuances (Details - Additional LPL shares)	9 Months Ended
	Apr. 30, 2021USD ($)$ / sharesshares
$0.10
Assumed Average Purchase Price Per Share | $ / shares	$ 0.10
Number of Shares to be Sold if Full Purchase | shares	17,118,038	[1]
Percentage of Outstanding Shares Owned After Giving Effect to the Shares Sold	17.00%	[2]
Proceeds from the Sale of Shares to LPC | $	$ 3,183,279	[1]
$0.25
Assumed Average Purchase Price Per Share | $ / shares	$ 0.25
Number of Shares to be Sold if Full Purchase | shares	17,118,038	[1]
Percentage of Outstanding Shares Owned After Giving Effect to the Shares Sold	17.00%	[2]
Proceeds from the Sale of Shares to LPC | $	$ 5,750,984	[1]
$0.81
Assumed Average Purchase Price Per Share | $ / shares	$ 0.81	[3]
Number of Shares to be Sold if Full Purchase | shares	10,837,685	[1]
Percentage of Outstanding Shares Owned After Giving Effect to the Shares Sold	12.00%	[2]
Proceeds from the Sale of Shares to LPC | $	$ 10,250,000	[1]
$1.00
Assumed Average Purchase Price Per Share | $ / shares	$ 1
Number of Shares to be Sold if Full Purchase | shares	8,778,525	[1]
Percentage of Outstanding Shares Owned After Giving Effect to the Shares Sold	10.00%	[2]
Proceeds from the Sale of Shares to LPC | $	$ 10,250,000	[1]
$1.25
Assumed Average Purchase Price Per Share | $ / shares	$ 1.25
Number of Shares to be Sold if Full Purchase | shares	7,022,820	[1]
Percentage of Outstanding Shares Owned After Giving Effect to the Shares Sold	9.00%	[2]
Proceeds from the Sale of Shares to LPC | $	$ 10,250,000	[1]
$1.50
Assumed Average Purchase Price Per Share | $ / shares	$ 1.50
Number of Shares to be Sold if Full Purchase | shares	5,852,350	[1]
Percentage of Outstanding Shares Owned After Giving Effect to the Shares Sold	8.00%	[2]
Proceeds from the Sale of Shares to LPC | $	$ 10,250,000	[1]
[1]	Although the Purchase Agreement provides that we may sell up to an additional $8,778,525 of our common stock to LPC, depending on the assumed average price per share, we may or may not be able to ultimately sell to Lincoln Park a number of shares of our common stock with a total value of $10,000,000 as the maximum number of shares to be sold totals 20,065,166. Following purchases and issuances made to date, 17,118,038 shares remained as of April 30, 2021.
[2]	The numerator is based on the maximum number of shares purchased at the corresponding assumed purchase price plus the 1,596,224 shares owned by LPC at January 31, 2021. The denominator is based on 91,610,202 shares outstanding as of January 31, 2021 plus the number of shares assumed purchased. The table does not give effect to the prohibition contained in the LPC Purchase Agreement that prevents us from selling to LPC the number of shares such that, after giving effect to such sale, LPC and its affiliates would beneficially own more than 4.99% of the then outstanding shares of our common stock.
[3]	The closing price of our common stock on April 30, 2021.

8. Common Stock Issuances (De_3

8. Common Stock Issuances (Details Narrative) - USD ($)	Mar. 01, 2021	Feb. 12, 2021	Aug. 14, 2020	Mar. 31, 2021	Feb. 28, 2021	Jan. 31, 2021	Apr. 30, 2021	Apr. 30, 2020	Jan. 31, 2021	Feb. 28, 2021	Mar. 31, 2021	Apr. 30, 2021	Apr. 30, 2020
Payment of placement agent fees												$ 169,000	$ 0
General and administrative expenses							$ 2,654,320	$ 867,665				$ 3,813,380	$ 2,690,140
Lincoln Park Capital Fund
Stock issued new, shares			602,422						200,000	330,106	1,020,798	2,153,326
Proceeds from sale of stock			$ 250,000						$ 35,080	$ 206,798	$ 979,597	$ 1,221,475
AGP [Member]
Payment of placement agent fees												$ 20,000
Warrants issued, common shares eligible			550,000
Warrants exercisable price per share			$ 0.50
Warrants issued, value			$ 220,000
Warrants expiration date			Aug. 6, 2024
Consulting Services Agreements | Consultant [Member]
Stock granted to related party	25,000	75,000				540,000
General and administrative expenses	$ 29,500	$ 93,750				$ 88,000
Purchase Agreement | Lincoln Park Capital Fund
Stock issued new, shares			793,802
Proceeds from sale of stock			$ 250,000
Initial Purchase [Member] | Lincoln Park Capital Fund
Stock issued new, shares			602,422
Convertible Promissory Note
Debt converted, amount converted			$ 100,000				230,000
Debt converted, interest converted			$ 7,000				$ 16,100
Debt converted, shares issued			214,000				298,165
Conversion price			$ 0.50		$ 0.83		$ 0.83			$ 0.83		$ 0.83
Stock issued new, shares					100,000
Convertible Promissory Note | Investors
Proceeds from sale of stock				$ 525,000	$ 689,500
Warrants issued, common shares eligible					960,834					960,834
Warrants exercisable price per share				$ 2	$ 1.23					$ 1.23	$ 2
Total closing costs				$ 250,950	$ 426,273
Number of stock sold				525,000	960,834

9. Related Party Transactions_2

9. Related Party Transactions (Details - Due to officers) - USD ($)	Apr. 30, 2021	Jul. 31, 2020
Total	$ 1,377	$ 27,902
Chief Executive Officer [Member]
Total	574	2,304
Chief Financial Officer [Member]
Total	$ 803	$ 25,598

9. Related Party Transactions_3

9. Related Party Transactions (Details - Accrued Compensation)	9 Months Ended
	Apr. 30, 2021USD ($)
Accrued wages, beginning balance	$ 211,702
Accrued wages, ending balance	246,872
J. Michael Redmond [Member]
Accrued wages, beginning balance	183,846
Salary accrued	0
Salary paid	0
Accrued wages, ending balance	$ 183,846

10. Going Concern (Details Narr

10. Going Concern (Details Narrative) - USD ($)	Apr. 30, 2021	Jul. 31, 2020	Apr. 30, 2020	Jul. 31, 2019
Risks and Uncertainties [Abstract]
Accumulated deficit	$ (42,833,232)	$ (28,850,728)
Cash and cash equivalents	$ 1,378,225	$ 62,952	$ 26,642	$ 167,095